ADG-116 is under clinical development by Adagene Suzhou and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ADG-116’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

ADG-116 overview

ADG-116 is under development for the treatment of solid tumors including pancreatic cancer, ovarian cancer and renal cell carcinoma, relapsed and refractory non-Hodgkin's lymphoma, liver cancer, melanoma and colon cancer. The drug candidate is developed based on dynamic precision library platform (DPL). It is administered through intravenous route. It acts by targeting CTLA-4. The drug candidate is developed based on Neobody technology. 

Adagene Suzhou overview

Adagene Suzhou (Adagene) is a biotechnology company which develops immune-oncology antibodies for the treatment of cancer. It is investigating ADG106, an agonist monoclonal antibody (mAb) to treat non-Hodgkin lymphoma and solid tumors. The company utilizes SAFEbody, a proprietary antibody masking technology which is activated only in disease tissues further reducing the spread of disease to the entire body and enhancing the therapeutic window for antibodies; and dynamic precision library (DPL) platform to advance antibody discovery. Adagene was funded by GP Healthcare Capital, Eight Roads Ventures, F-Prime Capital Partners, General Atlantic and other companies. The company has operations in San Francisco, California, the US. Adagene is headquartered in Suzhou, Jiangsu, China.

For a complete picture of ADG-116’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.